Literature DB >> 18586364

US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination.

Isabel G Jacobson1, Tyler C Smith, Besa Smith, Timothy S Wells, Robert J Reed, Margaret A K Ryan.   

Abstract

This study explores adverse events severe enough to warrant hospitalization that may have been associated with receiving the smallpox vaccine in conjunction with military service. Cox proportional hazards modeling was used to identify the risk of hospitalization among US active-duty military personnel during a 1-year period following receipt of the smallpox vaccine. The reference group consisted of active-duty military personnel who also received the smallpox vaccine after the conclusion of their health care observation period, allowing for comparison to a temporally and demographically similar population. The risk of hospitalization was slightly elevated among the postvaccine group for any-cause hospitalization and for hospitalization in several broad diagnostic categories. Hospitalizations for asthma, autoimmune diseases, and myopericarditis, were more likely in the postvaccine group. The increased risk of hospitalization for varied outcomes does not necessarily imply a cause-effect relationship, but it does offer areas for more focused study, using longitudinal data to explore the long-term impact of smallpox vaccination on the health of young adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586364     DOI: 10.1016/j.vaccine.2008.05.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.

Authors:  Leonard Moise; R Mark Buller; Jill Schriewer; Jinhee Lee; Sharon E Frey; David B Weiner; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

2.  A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.

Authors:  Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Brian A Hemann; Barnett T Gibbs; J Edwin Atwood; Robin S Howard; Audrey S Chang; Daniel L Cruser; Daniel G Gates; Marina N Vernalis; Marguerite S Lengkeek; Bruce M McClenathan; Allan S Jaffe; Leslie T Cooper; Steve Black; Christopher Carlson; Christopher Wilson; Robert L Davis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  Atypical Clinical Presentation of Monkeypox Complicated by Myopericarditis.

Authors:  Darrell H S Tan; Shelby Jaeranny; Maggie Li; Sharon S Sukhdeo; Juan Carlos Monge; Matias F Callejas; Maan Hasso; Ramzi Fattouh; Spencer D Lalonde; Jeffrey Lam; Sharmistha Mishra
Journal:  Open Forum Infect Dis       Date:  2022-08-03       Impact factor: 4.423

Review 4.  Defending against smallpox: a focus on vaccines.

Authors:  Emily A Voigt; Richard B Kennedy; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2016-04-28       Impact factor: 5.217

5.  Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.

Authors:  Massimiliano Bissa; Sole Maria Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen; Elena Illiano; Francesca Granucci; Ivan Zanoni; Achille Broggi; Antonia Radaelli
Journal:  Virus Res       Date:  2013-09-16       Impact factor: 6.286

6.  Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity.

Authors:  Massimiliano Bissa; Elena Quaglino; Carlo Zanotto; Elena Illiano; Valeria Rolih; Sole Pacchioni; Federica Cavallo; Carlo De Giuli Morghen; Antonia Radaelli
Journal:  Antiviral Res       Date:  2016-09-13       Impact factor: 10.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.